The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 14, 2014
Filed:
Feb. 05, 2013
Applicant:
Roche Glycart Ag, Schlieren-Zürich, CH;
Inventors:
Pablo Umaña, Zürich, CH;
Peter Bruenker, Hittnau, CH;
Claudia Ferrara, Zürich, CH;
Tobias Suter, Baden, CH;
Assignee:
Roche GlycArt AG, Schlieren-Zürich, CH;
Primary Examiner:
Int. Cl.
CPC ...
C12P 21/04 (2006.01); C12P 21/08 (2006.01); C07K 16/28 (2006.01); C12N 9/24 (2006.01); C07K 16/30 (2006.01); C12N 15/62 (2006.01); C12N 9/10 (2006.01); C07K 16/32 (2006.01); C12P 21/00 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); C12Y 302/01024 (2013.01); C07K 2317/732 (2013.01); A61K 38/00 (2013.01); C12Y 204/01144 (2013.01); C12N 9/2488 (2013.01); C07K 16/30 (2013.01); C12N 15/62 (2013.01); C07K 2317/24 (2013.01); C07K 16/2896 (2013.01); C12Y 302/01096 (2013.01); C12N 9/1051 (2013.01); A61K 2039/505 (2013.01); C12Y 204/01038 (2013.01); C07K 16/32 (2013.01); C12P 21/005 (2013.01); C07K 16/28 (2013.01); C07K 16/2863 (2013.01); C12Y 302/01114 (2013.01); C07K 2319/05 (2013.01); C07K 2317/41 (2013.01);
Abstract
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to nucleic acid molecules, including fusion constructs, having catalytic activity and the use of same in glycosylation engineering of host cells to generate polypeptides with improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.